tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate | 1141894-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate
• 英文别名: 1,1-Dimethylethyl 4-[({[2-(trifluoromethyl)phenyl]methyl}amino)-carbonyl]-1-piperidinecarboxylate；tert-butyl 4-[[2-(trifluoromethyl)phenyl]methylcarbamoyl]piperidine-1-carboxylate
• CAS: 1141894-92-9
• 化学式: C₁₉H₂₅F₃N₂O₃
• 分子量: 386.414
• InChiKey: RENCZGHHPJOVOH-UHFFFAOYSA-N

物化性质

• 沸点：
  496.7±45.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 11.0h， 生成 1-[2-methyl-6-(methylamino)pyridin-4-yl]-N-{[2-(trifluoromethyl)phenyl]methyl}piperidine-4-carboxamide
  参考文献：
  名称：

  Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase

  摘要：

  1-(1,3,5-Triazin-yl)piperidine-4-carboxamide inhibitors of soluble epoxide hydrolase were identified from high through-put screening using encoded library technology. The triazine heterocycle proved to be a critical functional group, essential for high potency and P450 selectivity. Phenyl group substitution was important for reducing clearance, and establishing good oral exposure. Based on this lead optimization work, 1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[[4-bromo-2-(trifluoromethoxy)]-phenyl]methyl}-4-piperidinecarboxamide (27) was identified as a useful tool compound for in vivo investigation. Robust effects on a serum biomarker, 9, 10-epoxyoctadec-12(Z)-enoic acid (the epoxide derived from linoleic acid) were observed, which provided evidence of robust in vivo target engagement and the suitability of 27 as a tool compound for study in various disease models. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.04.019
• 作为产物：
  描述：

  1-Boc-4-哌啶甲酸 在 三乙胺 作用下， 反应 13.0h， 生成 tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate
  参考文献：
  名称：

  融合的可溶性环氧水解酶/过氧化物酶体增殖物激活的受体调节剂的设计与合成†

  摘要：

  代谢综合症（MetS）是一个广泛而复杂的疾病群，由高血压，动脉粥样硬化，血脂异常和II型糖尿病组成。MetS的治疗需要多种药物，导致复杂的多药房。多目标化合物可能会减少MetS患者中所需药物的数量。在这项研究中，我们融合了可溶性环氧化物水解酶（sEH）抑制剂和过氧化物酶体增殖物激活受体（PPAR）激动剂的三种不同药效。最有前途的融合支架表现出多目标活性，并代表了设计和评估融合sEH / PPAR调节剂的有价值的起点。

  DOI：

  10.1039/c6md00042h

文献信息

• [EN] NOVEL sEH INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE sEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009097475A1

  公开（公告）日：2009-08-06

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I:(I) wherein R1, R2, R3, R5, R6, R13, A, B, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及新型sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体而言，该发明涉及符合以下式(I)的化合物：(I)其中R1、R2、R3、R5、R6、R13、A、B、Y、Z、x和m在此处定义，并其药学上可接受的盐。该发明的化合物是sEH抑制剂，可用于治疗通过sEH酶介导的疾病，如高血压。因此，该发明进一步涉及包括该发明的化合物的药物组合物。该发明还进一步涉及使用该发明的化合物或包含该发明的化合物的药物组合物来抑制sEH和治疗与之相关的疾病的方法。
• [EN] NOVEL SEH INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009097474A1

  公开（公告）日：2009-08-06

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3, R5a, R6a, A, B, K, L, M, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，该发明涉及符合以下式（I）的化合物：其中R1、R2、R3、R5a、R6a、A、B、K、L、M、Y、Z、x和m在此处定义，并且其药用盐。该发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，如高血压。因此，该发明还涉及包含该发明化合物的药物组合物。该发明还涉及使用该发明化合物或包含该发明化合物的药物组合物抑制sEH和治疗与之相关的疾病的方法。
• [EN] NOVEL SEH INHIBITORS AND THEIR USE<br/>[FR] INHIBITEURS INÉDITS DE LA SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009049165A1

  公开（公告）日：2009-04-16

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及新颖的sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体而言，该发明涉及符合以下式I的化合物：(I) 其中R1、R2、R3、R5a、R6a、A、B、Y、x和m的定义如下，并且其药用盐。该发明的化合物是sEH抑制剂，可用于治疗通过sEH酶介导的疾病，如高血压。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制sEH和治疗与之相关的疾病的方法。
• NOVEL sEH INHIBITORS AND THEIR USE
  申请人：Ding Yun

  公开号：US20100210628A1

  公开（公告）日：2010-08-19

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及按式I定义的化合物，其中R1、R2、R3、R5a、R6a、A、B、Y、x和m如下所定义，以及其药学上可接受的盐。本发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，如高血压。因此，本发明还涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物抑制sEH和治疗与其相关的疾病的方法。
• sEH inhibitors and their use
  申请人：Glaxosmithkline, LLC

  公开号：US08008483B2

  公开（公告）日：2011-08-30

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及符合式I的化合物：其中R1、R2、R3、R5a、R6a、A、B、Y、x和m如下所定义，以及其药学上可接受的盐。本发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，如高血压。因此，本发明还涉及包含本发明化合物的制药组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的制药组合物抑制sEH和治疗与之相关的病症的方法。